Rosuvastatin

Rosuvastatin calcium

Rosuvastatin is the most potent statin per milligram, lowering LDL-C and ApoB by 40-55% at standard doses. With strong outcomes data from JUPITER and ASTEROID, it is the default high-intensity statin for ApoB-guided lipid optimization.

HMG-CoA reductase inhibitor (statin)Prescription requiredEvidence A

⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

Lifetime cumulative ApoB exposure is the single best-validated modifiable driver of atherosclerotic cardiovascular disease, the leading cause of death in men. Rosuvastatin lowers ApoB by upregulating hepatic LDL receptors, reducing not just LDL-C but the entire spectrum of atherogenic particles. The JUPITER trial showed a 44% reduction in major cardiovascular events in primary prevention patients with elevated hsCRP. For longevity-focused men, even modest doses (5-10 mg) often achieve ApoB targets under 60 mg/dL. The drug also lowers hsCRP independent of lipid effects, reflecting a vascular anti-inflammatory action. Rosuvastatin has a long half-life and renal clearance, making it forgiving on timing and unlikely to interact with common medications. A small absolute increase in type 2 diabetes incidence exists, but the cardiovascular benefit outweighs this risk in nearly every population studied, including young men with elevated ApoB.

Uses

Label uses (approved)

Primary hypercholesterolemia
Mixed dyslipidemia
Secondary prevention of ASCVD
Primary prevention in elevated hsCRP (JUPITER population)
Homozygous familial hypercholesterolemia
Slowing atherosclerosis progression

Off-label (educational only)

ApoB-guided lipid lowering for longevity — Lifetime cumulative ApoB exposure is the primary driver of atherosclerosis; aggressive early lowering may reduce lifetime ASCVD risk
Lp(a)-elevated patients (alongside ApoB lowering) — Does not lower Lp(a) but reduces concurrent ApoB burden

Dosing

Label dose

5-40 mg orally once daily

Off-label / biohacker dose

2.5-10 mg daily for longevity-focused ApoB lowering; 5 mg every other day for statin-intolerant patients

Titration: Start 5-10 mg; recheck lipids and ALT at 4-12 weeks; titrate to ApoB target (<60 mg/dL for high-risk, <80 mg/dL primary prevention). Asian patients may require lower starting dose due to higher plasma exposure.

When to take: Take once daily at any consistent time, with or without food. Rosuvastatin's half-life is roughly 19 hours, much longer than short-acting statins like simvastatin or lovastatin, which means evening dosing offers no biological advantage. Starting doses range from 5 to 10 mg for primary prevention and ApoB-guided lipid lowering, escalating to 20 to 40 mg only when targets are not met. Asian ancestry is associated with roughly twice the systemic exposure at any given dose, so starting doses in patients of East Asian descent are typically 5 mg. Hold the dose for 24 hours if you develop unexplained, severe muscle pain or dark urine, and seek same-day medical evaluation.

Side effects & warnings

Common

Myalgia (5-10%)
Headache
Nausea
Constipation
Mild ALT elevation

Uncommon but serious

Myopathy
New-onset type 2 diabetes (modest absolute risk)
Cognitive complaints (rare, reversible)
Proteinuria at high doses
Hematuria

Serious warnings

Rhabdomyolysis (rare, <0.1%), severe hepatotoxicity (rare), drug-induced lupus (very rare). Contraindicated in active liver disease and pregnancy.

Biomarkers affected

apob

decrease

40-55% ApoB reduction at standard doses; upregulates hepatic LDL receptors

Evidence: strong

fasting glucose

variable

Small increase in fasting glucose observed across statin meta-analyses; minor clinical magnitude

Evidence: weak

hba1c

variable

Small HbA1c increase contributing to new-onset diabetes signal; absolute risk small

Evidence: weak

hscrp

variable

Lowers hsCRP by ~37% in JUPITER trial, independent of LDL-C effect

Evidence: strong

ldl c

decrease

40-55% LDL-C reduction; dose-dependent; STELLAR trial established potency

Evidence: strong

Monitoring

Lipid panel plus ApoB at baseline and 4 to 12 weeks after starting or after any dose change, then annually once stable. ALT at baseline and only if hepatic symptoms develop; routine liver enzyme monitoring on statins is no longer guideline-recommended in asymptomatic patients. Creatine kinase (CK) is checked only if muscle symptoms appear; routine CK screening leads to over-discontinuation in patients with benign elevations. HbA1c every 6 to 12 months since high-intensity statins raise the absolute risk of new-onset type 2 diabetes by roughly 0.1 to 0.3 percent per year. eGFR at baseline and annually; doses above 10 mg are avoided in severe renal impairment (creatinine clearance under 30 mL/min). Confirm patient is not pregnant or planning pregnancy at every visit, since statins are contraindicated in pregnancy.

The honest risk picture

The most common adverse effect is muscle aching, reported in 5-10% of patients. True myopathy with CK elevation is rare (<1%). Severe rhabdomyolysis is exceptional (<0.1%) but a medical emergency. A small absolute increase in new-onset type 2 diabetes has been documented across statin trials, on the order of one extra case per 1,000 patient-years at high-intensity doses. Mild ALT elevation is common; severe hepatotoxicity is rare. Statins are contraindicated in pregnancy. Cognitive complaints have been reported anecdotally but are not supported by controlled trials. Drug interactions are fewer than with other statins because rosuvastatin is not significantly metabolized by CYP3A4, but caution with cyclosporine, gemfibrozil, and certain HIV protease inhibitors is required. Patients with severe renal impairment should not exceed 10 mg daily. Always discuss persistent muscle symptoms with a clinician rather than self-discontinuing, since the nocebo effect is significant and most muscle complaints are not biochemically true myopathy.

Practical context

Cost (US, retail)

$15/mo

Legality

FDA-approved; Rx required. Generic widely available since 2016.

Interactions

true

FAQ

Does rosuvastatin cause diabetes?+

There is a small absolute increase in new-onset type 2 diabetes (~1 case per 1,000 patient-years on potent statins). The cardiovascular benefit outweighs this risk for the vast majority of patients, especially those with elevated ApoB.

How is rosuvastatin different from atorvastatin?+

Rosuvastatin is more potent on a mg-for-mg basis, has a longer half-life (~19h vs ~14h), and is renally cleared rather than hepatically metabolized, so it has fewer drug interactions via CYP3A4.

When should I take rosuvastatin?+

Anytime, but consistency matters. The long half-life means morning or evening dosing both work.

References (5)+

The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.